| Application no. and date | 10759491.3 (espacenet) (Federated) (European Patent Register), 20100402 | | Patent/reg. no. and date | DK/EP 2413933, 20171101 | | Publication date | 20120208 | | Priority no. and date | US 166097 P, 20090402 | | EP pub. no. and date |
EP 2413933 20120208 | | Effective date | | | Applicant/owner | Colucid Pharmaceuticals, Inc., 2530 Meridian Parkway, Suite 300
Durham, NC 27713, US | | Applicant ref. no. | P81803952DK00E | | Inventor | PILGRIM, Alison, 7651 Country Club Drive
La Jolla
CA 92037, US,
WHITE, James, F., 52 Daniels Lane
Carlisle
MA 01741, US,
RUPNIAK, Nadia, M., J., 808 Alden Bridge Drive
Cary
NC 27519, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/4545 (2006.01) , A61P 25/06 (2006.01) , C07D 403/02 (2006.01) , C07D 403/12 (2006.01) | | Title | 2,4,6-trifluor-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamid til behandling af migræne via oral eller intravenøs indgivelse | | Int. application no. | US2010029810 | | Int. publication no. | WO2010115125 | | Related patent (certificate) | CA 2023 00001 | | Status | Ændret DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
